Format

Send to

Choose Destination
Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29.

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Author information

1
Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas 78284-7840, USA.

Abstract

PURPOSE OF REVIEW:

We examine the role of 5-alpha reductase inhibitors in prevention and diagnosis of prostate cancer, highlight the basic science supporting this role, and analyze the phase III clinical trials addressing the association between 5-alpha reductase inhibitor use and prostate cancer.

RECENT FINDINGS:

To date, the Prostate Cancer Prevention trial (PCPT) is the only reported phase III randomized clinical trial to evaluate the role of 5-alpha reductase inhibitors in the prevention and treatment of prostate cancer. The original PCPT data revealed that finasteride reduced the risk of prostate cancer by approximately 25% in comparison with placebo. However, patients who received finasteride had a greater incidence of high-grade tumors, which prohibited acceptance of finasteride as a chemopreventive agent by most urologists. Recent updates of the PCPT findings confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to its effects on improving the performance characteristics of prostate-specific antigen and prostate biopsy. There was no increase in high-grade prostate cancer. Rather, there was improved detection of high-grade prostate cancer due to decreased prostate volume.

SUMMARY:

Finasteride is a valuable chemopreventive tool because it reduces the risk of prostate cancer, including high-grade cancer, and enhances our ability to detect high-grade disease.

PMID:
19318950
DOI:
10.1097/MOU.0b013e328329eb29
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center